- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01675102
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) (17p-CLL)
Allogeneic HSCT in 17p- CLL in First or Second Partial or Complete Remission at Transplant: a Non-interventional Prospective Study.
17p-/p53-mutated chronic lymphocytic leukemia (CLL) is an orphan disease, accounting for approximately 5% of newly diagnosed CLL. This subgroup of patients has a very poor outcome after chemoimmunotherapy. Allogeneic HCT may change the poor prognosis. In a retrospective EBMT-analysis on 44 patients with advanced 17p-CLL 2-year progression-free survival was 45% (95% CI, 30% to 60%) after allogeneic HCT (Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol, 2008, 26, 5094-5100).
Referring to these favorable results and small additional series, patients with 17p-CLL requiring therapy are considered to have an indication for allogeneic transplantation by many CLL study groups. Several CLL study groups recommend allogeneic HCT in 17p-CLL as part of the first- or second line treatment.
The aim is to collect additional evidence on allogeneic HCT in 17p-/p53-mutated CLL in first or second remission by a non-interventional prospective study. Patients shall be registered prior to HCT at the Leiden Office in order to rule out a reporting bias after transplantation.
Study Overview
Status
Conditions
Detailed Description
Objective:
The aim is to determine early PFS after allogeneic HCT in first or second remission of 17p-/p53-mutated CLL within an epidemiologic study.
Methods:
Neither the decision for allogeneic transplantation nor specific treatment recommendations for patients with 17p-/p53-mutated CLL are part of the study. Instead, the study protocol refers to EBMT guidelines. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21, 2007, 12-17). Minimal essential data (MED) A and B, defined by the EBMT, will be collected (www.ebmt.org).
The rate of progression-free survival (PFS) at 1 year after HSCT was selected as primary endpoint. Death, clinical relapse or progression but not immune manipulations (taper of immunosuppression, DLI, rituximab) are considered as treatment failure for PFS. Patients without information on one-year follow up will be considered as having experienced treatment failure. The rate of PFS at 1 year will be calculated by dividing the number of patients without treatment failure by the number of patients who met all selection criteria.
For the calculation of the sample size a fixed sample design was selected. The null hypothesis is that the success-rate for PFS is equal or less than 50%. Referring to the retrospective EBMT survey, PFS at one year after allogeneic HCT is expected to be 70%. According to Fleming-A'Hern (1982) the null hypothesis can be rejected with a power of 80% and an alpha error of 5% if a minimum of 24 out of 37 informative patients did not experience treatment failure during the first year after allogeneic HCT (Machin et al, Sample Size Tables for Clinical Studies, Wiley-Blackwell, 3rd edition, 2009). Taking into account a 10% drop-out rate by violation of inclusion criteria the target number of patients to be included was set at 41 patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- Rigshospitalitet
-
-
-
-
-
Helsinki, Finland
- University Central Hospital
-
-
-
-
-
Dresden, Germany
- Universitaetsklinikum
-
Hamburg, Germany
- University Hospital Eppendorf
-
Heidelberg, Germany
- University of Heidelberg
-
Ulm, Germany
- Klinik fuer Innere Medzin III
-
-
-
-
-
Tel-Hashomer, Israel
- Chaim Sheba Medical Centre
-
-
-
-
-
Maastricht, Netherlands
- University Hospital
-
-
-
-
-
Lund, Sweden
- University Hospital
-
-
-
-
-
Nottingham, United Kingdom
- City Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 17p-/p53-mutated CLL by FISH or sequencing, confirmed by review by an experienced laboratory
- first or second partial remission or complete remission at HCT according to the updated NCI-criteria (Hallek 2008)
- MRD diagnostic as part of the local standard follow up
- allogeneic HCT from a matched related or unrelated donor with up to one mismatch refering to HLA-A, -B, -C and DRB1
Exclusion Criteria:
- ex vivo T-cell depletion
- in vivo T-cell depletion with alemtuzumab
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival (PFS) rate
Time Frame: 1 year after HSCT
|
1 year after HSCT
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of MRD-negative complete remissions
Time Frame: 1 year after HSCT
|
1 year after HSCT
|
Overall survival, cumulative incidence of relapse and non-relapse mortality
Time Frame: 1 year after HSCT
|
1 year after HSCT
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Nicolaus kroeger, MD, BMT Centre, University Hospital Eppendorf, Hamburg, Germany
- Principal Investigator: Johannes Schetelig, MD, Medizinische Klinik und Poliklinik I, University Hospital Dresden, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EBMT-42204420
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CLL
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Nanfang Hospital, Southern Medical UniversityNot yet recruiting
-
Peking University People's HospitalRecruiting
-
Dana-Farber Cancer InstituteGlaxoSmithKline; National Comprehensive Cancer NetworkTerminatedCLL | SLLUnited States
-
Niguarda HospitalRecruitingCLL TransformationItaly, Switzerland
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Rigshospitalet, DenmarkKarolinska Institutet; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaboratorsRecruitingCLLDenmark, Sweden, Netherlands
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruiting
-
MEI Pharma, Inc.Kyowa Kirin, Inc.Withdrawn
-
Stichting Hemato-Oncologie voor Volwassenen NederlandRecruitingCLL/SLLNetherlands, Belgium, Denmark